Key facts
- European shares rose to near one-week highs on Tuesday.
- Genmab climbed 7.6% after its blood cancer drug combination showed positive late-stage study results.
- The broader healthcare sector was up 1.6%.
- Euro zone bond yields eased, having touched multi-decade highs last week.
- The French government is seeking to enact an unpopular 2027 budget to lower its deficit.
- The euro hovered near a 17-month low due to political uncertainty in Spain.
European shares edged higher on Tuesday, recouping some losses from the previous session, as gains in healthcare stocks, led by Genmab, boosted the pan-European STOXX 600 index. The index was up 0.8% to 638.41 points by 0727 GMT, poised for a third consecutive session of gains.
Genmab climbed 7.6% after the Danish biotech firm and US drugmaker AbbVie's blood cancer drug combination cut the risk of progression or death in a late-stage study. The broader healthcare sector followed suit, rising 1.6%.
Attention is now focused on upcoming euro zone retail sales data and the UK S&P Global PMI survey, which could provide insights into consumer spending and economic activity.
The euro remained near a 17-month low, pressured by political uncertainty following Spanish Prime Minister Pedro Sanchez's call for a snap election on Monday. Meanwhile, the French government's efforts to enact an unpopular 2027 budget to lower its deficit have sparked concerns in the bond market. Despite these fiscal worries, euro zone bond yields eased, having reached multi-decade highs in the prior week.
Among other notable movers, Italy's Technoprobe gained 2.3% after J.P.Morgan initiated coverage with an 'overweight' rating.
